RE:RE:RE:ONCY May 09, 2024 Earnings CallTranscript Interestingly Pfizer was particularly mentioned in the earnings call by Thomas Heineman, as though it was done for a specific reason other than to simply mention their CDK4/6 Ibrance's approval based on its 165 patient Paloma 1 study.
Ibrance's patent expires in 2027 and ONCY's pelareorep is synergistic with this soon-to-be off-patent breast cancer therapy. In 2021 Ibrance generated US$5.43 Billion in annual sales for Pfizer, declining to US$5.12 Billion in 2022.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71159-3/abstract
"It is notable, for example, that Pfizer';s CDK4/6 inhibitor received its initial approval in breast cancer based on the 165 patient [indiscernible] 1 study. On the topic of our upcoming Type C meeting, as Matt indicated, defining the registrational path for pela in breast cancer is a major goal for Oncolytics in 2024. Earlier this year, we submitted a Type C meeting request to the FDA and the meeting will take place in the second quarter of 2024. At this meeting will discuss our proposed next breast cancer clinical trial with the FDA including the anticipated study design, study population and study endpoints. Through this interaction, we expect to align with the agency on the optimal clinical approach, which will allow us to move forward confidently as we continue to develop code as a treatment option for breast cancer patient."